Identifying biomarkers for IBD diagnosis and management
Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.
Identifying biomarkers for IBD siagnosis and management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.
Attend this webinar to:
- Explore the role of biomarkers in tailoring medical care and enhancing precision in pediatric IBD treatment
- Uncover serum proteins intricately linked to TNF inhibitor response, gaining insights for improved therapeutic decision-making in IBD
- Discover how the SomaScan® 11K Assay transforms non-invasive biomarker discovery, revolutionizing differential pediatric IBD diagnosis
Towia A. Libermann, PhD
Associate Professor, Medicine, Harvard Medical School
Assistant Professor of Medicine, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center
Director of BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center
Towia A. Libermann, Ph.D. is an Associate Professor of Medicine in the Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Libermann is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Center and of the Dana Farmer/Harvard Cancer Center Cancer Proteomics Core. Dr. Libermann is an internationally recognized translational investigator with a strong track record in precision medicine, biomarker discovery and translational studies of immunological diseases and cancer. Dr. Libermann’s lab is focused on applying multi-omics approaches to identify proteins or genes that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. Dr. Libermann has been at the forefront of the next generation of proteomics and plays a central role in driving biomarker discovery to the next level. Libermann’s group uses the aptamer-based SomaScan proteomics platform, a modified aptamer-based high multiplex immunoassay platform, to discover and validate diagnostic, predictive, and prognostic biomarkers for various diseases using liquid biopsies such as extracellular vesicles and body fluids. Using the latest in machine learning, Libermann’s group has developed predictor models for applications in early detection, disease diagnosis, prediction of therapeutic response, monitoring of disease progression, and outcome prediction. Dr. Libermann received his PhD in Immunology in 1986 from the Weizmann Institute of Science and Technology, Rehovot and did a postdoctoral fellowship at the Whitehead Institute, Cambridge.
Identifying biomarkers for IBD diagnosis and mnagement
A presentation by Towia Libermann, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.